Metabolic and Metabolomics Insights into Dilated Cardiomyopathy

Author:

Ampong IsaacORCID

Abstract

<b><i>Background:</i></b> Dilated cardiomyopathy (DCM) is the most common form of heart muscle disease characterized by progressive dilatation and ventricular dysfunction. Metabolomics is an emerging and powerful discipline that provides a global information on the phenotype of mammalian systems via the study of endogenous and exogenous metabolites in cells, tissues, and biofluids. These studies aid in the identification of biomarkers to prevent diseases in later life or help to early detect onset of diseases as well as aiding in the elucidation of disease mechanisms. <b><i>Summary:</i></b> Metabolomics provides a unique opportunity to discover novel biomarkers for DCM. This review demonstrates evidence of metabolite-based biomarkers useful for predicting, diagnosing, and monitoring therapeutic interventions of DCM. Key metabolites identified as potential biomarkers for diagnosing DCM include acylcarnitines, succinic acid, malate, methylhistidine, aspartate, methionine, and phenylalanine. In terms of differentiating DCM from ischemic cardiomyopathy, potential biomarkers including 1-pyrroline-2-carboxylate, norvaline, lysophosphatidylinositol (16:0/0:0), phosphatidylglycerol, fatty acid esters of hydroxy fatty acid, and phosphatidylcholine were identified. Acylcarnitines, isoleucine and linoleic acid, and tryptophan were the main biomarkers to monitor treatment response to DCM. Mapping metabolites to metabolic pathways revealed dysregulation of branch-chain amino acid, glycolysis, tricarboxylic acid cycle, and triacylglycerol and pentose phosphate metabolism, which have the therapeutic potential for DCM. This review shows several limitations including the use of small sample sizes, lack of interpretation of age and sex differences in most studies, and the fact that studies have so far been limited to case-control study designs. <b><i>Key Messages:</i></b> Metabolites have close proximity to disease phenotype. With recent advances in metabolomics field, potential biomarkers for DCM have been identified based on studies using different biological and metabolomics technologies. However, multicenter studies with larger populations that will lead to validation of these identified biomarkers to enable their clinical translation and utilization are still needed.

Publisher

S. Karger AG

Subject

Nutrition and Dietetics,Medicine (miscellaneous)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3